DAVID WILSON;TEVA PHARMACEUTICALS AUSTRALIA PTY LTD;TETSUYA TAURA
发明人:
DAVID WILSON,TETSUYA TAURA
申请号：
IL22708113
公开号：
IL227081A
申请日:
2013.06.20
申请国别(地区):
IL
年份:
2018
代理人:
摘要：
The present invention relates to antibodies, immunoglobulin constructs or immunoglobulin IgG4 fusion proteins whose in vivo half-lives are increased by the combination of (i) a modified IgG4 Fc region or FcRn binding domain thereof and (ii) a modified IgG4 hinge region sequence.
